PROVAXIM Trademark

Trademark Overview


On Wednesday, August 26, 1998, a trademark application was filed for PROVAXIM with the United States Patent and Trademark Office. The USPTO has given the PROVAXIM trademark a serial number of 75543042. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Friday, July 11, 2003. This trademark is owned by Connaught Technology corporation. The PROVAXIM trademark is filed in the Pharmaceutical Products category with the following description:

HUMAN VACCINES

General Information


Serial Number75543042
Word MarkPROVAXIM
Filing DateWednesday, August 26, 1998
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateFriday, July 11, 2003
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing1000 - Typeset: Word(s) / letter(s) / number(s)
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesHUMAN VACCINES

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, October 1, 1998
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameConnaught Technology corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressGreenville, DE 19807

Trademark Events


Event DateEvent Description
Friday, July 11, 2003ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Monday, November 4, 2002NON-FINAL ACTION MAILED
Tuesday, September 4, 2001ASSIGNED TO EXAMINER
Friday, April 9, 1999LETTER OF SUSPENSION MAILED
Friday, April 9, 1999ASSIGNED TO EXAMINER
Thursday, April 8, 1999ASSIGNED TO EXAMINER
Thursday, April 8, 1999ASSIGNED TO EXAMINER

Related Keywords


provaxim vaccines human